Adding bempedoic acid to cholesterol treatment after an acute coronary syndrome
Tests adding bempedoic acid to statin and ezetimibe in adults after acute coronary syndrome.
Plain-language title generated from the registry record
Registry title: Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome
Key facts
- Where
- Taipei, TaiwanSee the site
- Phase
- Phase 4
Where in Taiwan
- Taipei Medical University HospitalTaipei, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Taipei Medical University Hospital
- Trial code
- NCT07824323
- Record updated
- 17 September 2026
- Original description
This randomized clinical trial will evaluate whether starting bempedoic acid in addition to high-intensity statin therapy and ezetimibe within 72 hours after percutaneous coronary intervention improves low-density lipoprotein cholesterol (LDL-C) control in adults with acute coronary syndrome. Participants will receive either triple therapy with a high-intensity statin, ezetimibe, and bempedoic acid or standard dual therapy with a high-intensity statin and ezetimibe for 12 weeks. The primary outcome is the proportion of participants with LDL-C below 55 mg/dL at Week 12. Changes in lipid and inflammatory markers, medication adherence, and treatment-emergent adverse events will also be assessed.Read full original descriptionShow less
EARLY-BIRD ACS Trial: Early Aggressive Lipid-Lowering Regimen With Bempedoic Acid Initiated for Reducing Dyslipidemia in Patients With Acute Coronary Syndrome
This randomized clinical trial will evaluate whether starting bempedoic acid in addition to high-intensity statin therapy and ezetimibe within 72 hours after percutaneous coronary intervention improves low-density lipoprotein cholesterol (LDL-C) control in adults with acute coronary syndrome. Participants will receive either triple therapy with a high-intensity statin, ezetimibe, and bempedoic acid or standard dual therapy with a high-intensity statin and ezetimibe for 12 weeks. The primary outcome is the proportion of participants with LDL-C below 55 mg/dL at Week 12. Changes in lipid and inflammatory markers, medication adherence, and treatment-emergent adverse events will also be assessed.
Inclusion: Age 18 years or older; Confirmed acute coronary syndrome, including ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, or unstable angina; Percutaneous coronary intervention within the preceding 72 hours; Baseline LDL-C of at least 70 mg/dL; Able and willing to provide written informed consent.
Exclusion: Current use of a PCSK9 inhibitor or fibrate at baseline; Known gallbladder disease, including cholelithiasis or previous cholecystitis; History of symptomatic hyperuricemia or gout; Active systemic infection or acute inflammatory disease that could interfere with hs-CRP interpretation; Severe hepatic impairment, defined as ALT or AST greater than 3 times the upper limit of normal at screening; Triglycerides of at least 400 mg/dL at screening; Known intolerance or contraindication to statins, ezetimibe, or bempedoic acid; Estimated glomerular filtration rate below 30 mL/min/1.73 m2 or dialysis; Current participation in another interventional clinical trial; Pregnancy, breastfeeding, or planned pregnancy during the study period.